marimastat has been researched along with Disease Models, Animal in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baxter, AD; Bhogal, R; Bird, J; Keily, JF; Manallack, DT; Montana, JG; Owen, DA; Pitt, WR; Watson, RJ; Wills, RE | 1 |
| Bulska, E; Kaczmarek, L; Khomiak, D; Konopka, A; Pijet, B; Pikul, S; Rejmak, E; Stefaniuk, M | 1 |
| Lin, IT; Lin, MY; Wang, IJ; Wu, YC | 1 |
| Christison-Lagay, ER; Doiron, RJ; Le, HD; Moses, MA; Nose, V; Novak, KB; Puder, M | 1 |
| Bloys, H; Kaijzel, EL; Löwik, CW; Snoeks, TJ; van Beek, E; van Hinsbergh, VW; van Wijngaarden, J | 1 |
| Gay, RE; Gay, S; Hummel, KM; Michel, BA; Neidhart, M; Seemayer, CA | 1 |
| Alwayn, IP; Andersson, C; Arsenault, DA; Bistrian, BR; Gura, KM; Lee, S; Moses, M; Nose, V; Puder, M; Zauscher, B | 1 |
| Fingleton, B; Matrisian, LM; Nelson, AR; Rothenberg, ML | 1 |
| Banai, S; Fishbein, I; Gertz, SD; Golomb, G; Margolin, L; Perez, LS; Reich, R | 1 |
| Horiuchi, M; Mita, S; Okahara, A; Oki, K; Sasano, M; Suhara, H; Tsuji, F; Yamanouchi, T | 1 |
10 other study(ies) available for marimastat and Disease Models, Animal
| Article | Year |
|---|---|
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
Topics: Animals; Antineoplastic Agents; Arthritis, Experimental; Disease Models, Animal; Enzyme Inhibitors; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Melanoma, Experimental; Mice | 2001 |
The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Drug Evaluation, Preclinical; Hydroxamic Acids; Kainic Acid; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice, Inbred C57BL; Nectins; Status Epilepticus | 2020 |
Stepwise candidate drug screening for myopia control by using zebrafish, mouse, and Golden Syrian Hamster myopia models.
Topics: Animals; Atropine; Cricetinae; Disease Models, Animal; Drug Evaluation, Preclinical; Embryo, Nonmammalian; Hydroxamic Acids; Lumican; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Morpholinos; Myopia; Phenylalanine; Sclera; Thiophenes; Tissue Inhibitor of Metalloproteinase-2; Zebrafish; Zebrafish Proteins | 2021 |
Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury.
Topics: Animals; Biomarkers; Blotting, Western; Creatinine; Disease Models, Animal; Hydroxamic Acids; Kidney; Kidney Tubular Necrosis, Acute; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Protease Inhibitors; Reperfusion Injury; Severity of Illness Index | 2010 |
An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510.
Topics: Angiogenesis Inhibitors; Animals; Benzene Derivatives; Capillaries; Cyclohexanes; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Hydroxamic Acids; In Vitro Techniques; Mice; Neovascularization, Pathologic; Neovascularization, Physiologic; O-(Chloroacetylcarbamoyl)fumagillol; Organophosphorus Compounds; Sesquiterpenes; Tubulin Modulators | 2010 |
Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo.
Topics: Adult; Animals; Arthritis, Rheumatoid; Cartilage; Cell Adhesion; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Female; Fibroblasts; Glycosaminoglycans; Humans; Hydroxamic Acids; In Vitro Techniques; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Mice; Mice, SCID; Microscopy, Electron; Middle Aged; Phenotype; Synovial Fluid | 2003 |
Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.
Topics: Animals; Dietary Carbohydrates; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Hydroxamic Acids; Interleukin-6; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; PPAR alpha; Treatment Outcome | 2006 |
Matrix metalloproteinases: biologic activity and clinical implications.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals | 2000 |
Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade.
Topics: Angioplasty, Balloon; Animals; Arteries; Cell Movement; Constriction, Pathologic; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Hydroxamic Acids; Hyperplasia; Male; Matrix Metalloproteinase Inhibitors; Muscle, Smooth, Vascular; Oligopeptides; Phenylalanine; Rats; Receptors, Vitronectin; Thiophenes; Tunica Intima | 2002 |
Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Antibodies; Arthritis, Experimental; Disease Models, Animal; Enzyme Inhibitors; Humans; Hydroxamic Acids; Lipopolysaccharides; Metalloendopeptidases; Mice; Mice, Inbred BALB C; Mice, Transgenic; Sepsis; Tumor Necrosis Factor-alpha | 2002 |